These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 34260845)
1. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Hindié E N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260845 [No Abstract] [Full Text] [Related]
2. Lenvatinib plus Pembrolizumab for Renal Cell Carcinoma. Reply. Motzer R; Choueiri TK N Engl J Med; 2021 Jul; 385(3):287. PubMed ID: 34260846 [No Abstract] [Full Text] [Related]
3. First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC. Romero D Nat Rev Clin Oncol; 2023 Oct; 20(10):661. PubMed ID: 37507496 [No Abstract] [Full Text] [Related]
4. [New drug approval: Lenvatinib plus pembrolizumab for advanced renal cell carcinoma]. Saillant A; Borchiellini D Bull Cancer; 2022; 109(7-8):737-738. PubMed ID: 35599170 [No Abstract] [Full Text] [Related]
5. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lee CH; Shah AY; Rasco D; Rao A; Taylor MH; Di Simone C; Hsieh JJ; Pinto A; Shaffer DR; Girones Sarrio R; Cohn AL; Vogelzang NJ; Bilen MA; Gunnestad Ribe S; Goksel M; Tennøe ØK; Richards D; Sweis RF; Courtright J; Heinrich D; Jain S; Wu J; Schmidt EV; Perini RF; Kubiak P; Okpara CE; Smith AD; Motzer RJ Lancet Oncol; 2021 Jul; 22(7):946-958. PubMed ID: 34143969 [TBL] [Abstract][Full Text] [Related]
6. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK; N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314 [TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. Grünwald V; Powles T; Choueiri TK; Hutson TE; Porta C; Eto M; Sternberg CN; Rha SY; He CS; Dutcus CE; Smith A; Dutta L; Mody K; Motzer RJ Future Oncol; 2019 Mar; 15(9):929-941. PubMed ID: 30689402 [TBL] [Abstract][Full Text] [Related]
8. The Efficacy of Lenvatinib and Everolimus in Chromophobe-type Non-Clear-Cell Renal Cell Carcinoma: A Case Report and Literature Review. Schwartz C; Pfanzelter N; Kuzel TM Clin Genitourin Cancer; 2017 Oct; 15(5):e903-e906. PubMed ID: 28624319 [No Abstract] [Full Text] [Related]
9. Lenvatinib plus pembrolizumab combination therapy for adult patients with advanced renal cell carcinoma. Ged Y; Lee CH Expert Rev Anticancer Ther; 2022 Oct; 22(10):1049-1059. PubMed ID: 36154355 [TBL] [Abstract][Full Text] [Related]
11. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors. Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766 [TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of pembrolizumab plus lenvatinib versus pembrolizumab and lenvatinib monotherapies in cancers: A systematic review. Mo DC; Luo PH; Huang SX; Wang HL; Huang JF Int Immunopharmacol; 2021 Feb; 91():107281. PubMed ID: 33338862 [TBL] [Abstract][Full Text] [Related]
14. Management of Adverse Reactions Related to Lenvatinib Plus Pembrolizumab Treatment Among Patients With Renal Cell Carcinoma. Grünwald V; Larkin J; Puente J; Bedke J; Porta C Clin Genitourin Cancer; 2024 Apr; 22(2):394-401. PubMed ID: 38218660 [TBL] [Abstract][Full Text] [Related]
15. Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001. Marth C; Tarnawski R; Tyulyandina A; Pignata S; Gilbert L; Kaen D; Rubio MJ; Frentzas S; Beiner M; Magallanes-Maciel M; Farrelly L; Choi CH; Berger R; Lee C; Vulsteke C; Hasegawa K; Braicu EI; Wu X; McKenzie J; Lee JJ; Makker V Int J Gynecol Cancer; 2022 Jan; 32(1):93-100. PubMed ID: 34799418 [TBL] [Abstract][Full Text] [Related]
16. The implementation of lenvatinib/everolimus or lenvatinib/pembrolizumab combinations in the treatment of metastatic renal cell carcinoma. Jacob A; Shook J; Hutson T Expert Rev Anticancer Ther; 2021 Apr; 21(4):365-372. PubMed ID: 33393393 [No Abstract] [Full Text] [Related]
17. Combined use of pembrolizumab and lenvatinib: A review. Eisinger C; Muluneh B J Oncol Pharm Pract; 2023 Sep; 29(6):1461-1466. PubMed ID: 37231712 [TBL] [Abstract][Full Text] [Related]
18. [New drug approval: Pembrolizumab plus lenvatinib in second line for patients with advanced or recurrent endometrial cancer]. De Jesus C; Rodrigues M Bull Cancer; 2022; 109(7-8):740-741. PubMed ID: 35672187 [No Abstract] [Full Text] [Related]
19. Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma. Glen H Future Oncol; 2016 Oct; 12(19):2195-204. PubMed ID: 27339111 [TBL] [Abstract][Full Text] [Related]
20. Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study. Garnick MB J Clin Oncol; 2013 Oct; 31(30):3746-8. PubMed ID: 24019543 [No Abstract] [Full Text] [Related] [Next] [New Search]